Glujey-PM2

Description

GLUJEY-PM2 is a potent, triple-action oral antidiabetic formulation by Ellanjey that combines Glimepiride, Pioglitazone and Metformin Hydrochloride (SR) – three complementary, well-established medications for the management of type 2 diabetes mellitus. This fixed-dose combination is indicated for patients who have inadequate glycemic control on dual therapy (metformin + sulfonylurea or metformin + pioglitazone) and require additional glucose lowering.

Key Benefits:

• Triple Mechanism of Action – Targets three primary defects of type 2 diabetes simultaneously.

• Glimepiride – Stimulates insulin release from the pancreas.

• Pioglitazone – Improves insulin sensitivity in fat, muscle & liver tissues.

• Metformin (SR) – Reduces liver glucose production & enhances peripheral glucose uptake.

• Comprehensive Glycemic Control – Lowers fasting & postprandial blood glucose effectively.

• Extended Release Metformin – Smoother blood levels with fewer gastrointestinal side effects.

• Insulin Resistance Management – Pioglitazone directly addresses the root cause of type 2 diabetes.

FAQs:

1. What is the advantage of adding Pioglitazone to Glimepiride and Metformin?
Pioglitazone directly targets insulin resistance – the root cause of type 2 diabetes. It also preserves beta-cell function and reduces cardiovascular risk, unlike glimepiride alone.

2. Does Glujey-PM2 cause weight gain?
Yes – both pioglitazone and glimepiride can cause mild to moderate weight gain (2-4 kg on average). Metformin is weight-neutral but cannot fully counteract this effect.

3. Is Pioglitazone safe for the heart?
Pioglitazone reduces cardiovascular events (heart attack, stroke) in high-risk patients. However, it can cause fluid retention and should not be used in patients with severe (NYHA Class III/IV) heart failure.

4. Why is Glujey-PM2 not recommended for patients with bladder cancer?
Long-term use of pioglitazone (over 1 year) has been associated with a small increased risk of bladder cancer. It should be avoided in patients with active or prior bladder cancer.